DelveInsight's "Alpha-Antitrypsin Deficiency - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Alpha-Antitrypsin Deficiency, historical and forecasted epidemiology as well as the Alpha-Antitrypsin Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Alpha-Antitrypsin Deficiency market report provides current treatment practices, emerging drugs, Alpha-Antitrypsin Deficiency market share of the individual therapies, current and forecasted Alpha-Antitrypsin Deficiency market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Alpha-Antitrypsin Deficiency treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Study Period: 2017-2030
Alpha Antitrypsin Deficiency (AATD) occurs when the body is unable to produce sufficient amounts of AAT protein, exposing the organs to harmful effects of proteolytic enzymes, such as neutrophil elastase. AAT protein, a protein made in the liver, plays an important role in protecting organs of the body such lungs from proteolytic enzymes, but some causes lead the protein to be unable to enter the bloodstream and work as desired, leading to increased risk of lung disease.
The DelveInsight Alpha Antitrypsin Deficiency (AATD) market report gives the thorough understanding of the AATD by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Alpha Antitrypsin Deficiency in the US and Europe.
The Alpha Antitrypsin Deficiency (AATD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 6 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population of AATD, total diagnosed population of AATD, genotype of AATD diagnosed pool and comorbidities associated with AATD) scenario of Alpha Antitrypsin Deficiency (AATD) in the 6MM covering United States and EU5 countries (Germany, Spain, Italy, France and United Kingdom) from 2017 - 2030.
According to DelveInsight, the total number of prevalent cases of Alpha Antitrypsin Deficiency (AATD) in 6 MM was found to be 175,009, in the year 2017.
This segment of the Alpha Antitrypsin Deficiency report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Current treatment for AATD includes both medicinal and surgical therapies. Both of these categories rely on providing symptomatic relief to the subjects based on the level and severity of their conditions. Commonly used therapy for AATD is similar to chronic obstructive pulmonary disease (COPD) and emphysema treatment: abstinence from smoking, long-acting bronchodilators, antibiotics, inhalations of corticosteroids, and long-acting beta-agonists are recommended.
However, the application of such solutions does not increase the functional AAT level in serum. The only currently approved and dedicated treatment for AATD is Augmentation therapy. Weekly intravenous supplementation with the AAT protein purified from pooled healthy donors' plasma that has become available since the end of the 1980s. It is based on the administration of the purified human AAT at a dose of 60 mg/kg per week in order to achieve the protective level of AAT in serum.
The Alpha Antitrypsin Deficiency market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Alpha Antitrypsin Deficiency in 6MM was found to be USD 698 Million in 2017, and is expected to increase during the course of the study period (2017–2030). Among the 6MM, the United States accounts for the largest market size of AATD, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain).
This section focusses on the rate of uptake of the potential drugs recently launched in the Alpha-Antitrypsin Deficiency market or expected to get launched in the market during the study period 2017-2030. The analysis covers Alpha-Antitrypsin Deficiency market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Alpha-Antitrypsin Deficiency key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Alpha-Antitrypsin Deficiency emerging therapies.
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
To keep up with current market trends, we take KOLs and SME's opinion working in Alpha-Antitrypsin Deficiency domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Alpha-Antitrypsin Deficiency market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
We perform Competitive and Market Intelligence analysis of the Alpha-Antitrypsin Deficiency Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Market Insights:
Epidemiology Insights:
What is Alpha Antitrypsin Deficiency?
Alpha Antitrypsin Deficiency occurs when the body is unable to produce sufficient amounts of Alpha Antitrypsin protein, exposing the organs to harmful effects of proteolytic enzymes, such as neutrophil elastase. Alpha Antitrypsin protein, a protein made in the liver, plays an important role in protecting organs of the body such lungs from proteolytic enzymes, but some causes lead the protein to be unable to enter the bloodstream and work as desired, leading to increased risk of lung disease.
How is epidemiology segmented for Alpha Antitrypsin Deficiency?
The total prevalent population of Alpha Antitrypsin Deficiency, total diagnosed population of Alpha Antitrypsin Deficiency, genotype of Alpha Antitrypsin Deficiency diagnosed pool and comorbidities associated with Alpha Antitrypsin Deficiency.
What was the Alpha Antitrypsin Deficiency total prevalent cases in 2017?
The total number of prevalent cases of Alpha Antitrypsin Deficiency in 6 MM was found to be 175,009 in the year 2016.
What was the Alpha Antitrypsin Deficiency market in 2017?
The market of Alpha Antitrypsin Deficiency in 6MM was found to be USD 698 Million in 2017.
Which companies are developing drugs for Alpha Antitrypsin Deficiency?
Kamada Ltd, Alnylam Pharmaceuticals, Arrow Head Pharmaceuticals, Vertex Pharmaceuticals, Mereo Biopharma, Dicerna Pharmaceuticals are developing drugs for Alpha Antitrypsin Deficiency.
1. Key Insights
2. Executive Summary of Alpha Antitrypsin Deficiency
3. SWOT Analysis for Alpha Antitrypsin Deficiency
4. Patient Share of Alpha Antitrypsin Deficiency at a Glance
4.1. Prevalent Cases (%) Distribution of Alpha Antitrypsin Deficiency in 2017
4.2. Prevalent Cases (%) Distribution of Alpha Antitrypsin Deficiency in 2030
5. Alpha Antitrypsin Deficiency Market Overview at a Glance
5.1. Market Share (%) Distribution of Alpha Antitrypsin Deficiency in 2017
5.2. Market Share (%) Distribution of Alpha Antitrypsin Deficiency in 2030
6. Disease Background and Overview
6.1. Introduction
6.2. Symptoms
6.3. Etiology
6.4. Risk Factors
6.5. Genetic Inheritance of AAT Deficiency
6.6. Clinical Manifestations
6.7. Pathophysiology
6.8. Biomarkers
6.9. Diagnosis
6.10. Diagnostic Delay
7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM
8. Country-wise Epidemiology of Alpha-1-Antitrypsin Deficiency
8.1. Assumptions and Rationale: 6MM
8.2. United States
8.2.1. Prevalence of Symptomatic AATD in the United States
8.2.2. Diagnosed population of AATD in the United States
8.2.3. Genotype of AATD Diagnosed patients in the United States
8.2.4. Comorbidity associated with AATD in the United States
8.3. EU5
8.3.1. Germany
8.3.1.1. Prevalence of Symptomatic AATD in Germany
8.3.1.2. Diagnosed population of AATD in Germany
8.3.1.3. Genotype of AATD Diagnosed patients in Germany
8.3.1.4. Comorbidity associated with AATD in Germany
8.3.2. France
8.3.2.1. Prevalence of Symptomatic AATD in France
8.3.2.2. Diagnosed population of AATD in France
8.3.2.3. Genotype of AATD Diagnosed patients in France
8.3.2.4. Comorbidity associated with AATD in France
8.3.3. Italy
8.3.3.1. Prevalence of Symptomatic AATD in Italy
8.3.3.2. Diagnosed population of AATD in Italy
8.3.3.3. Genotype of AATD Diagnosed patients in Italy
8.3.3.4. Comorbidity associated with AATD in Italy
8.3.4. Spain
8.3.4.1. Prevalence of Symptomatic AATD in Spain
8.3.4.2. Diagnosed population of AATD in Spain
8.3.4.3. Genotype of AATD Diagnosed patients in Spain
8.3.4.4. Comorbidity associated with AATD in Spain
8.3.5. United Kingdom
8.3.5.1. Prevalence of Symptomatic AATD in the United Kingdom
8.3.5.2. Diagnosed population of AATD in the United Kingdom
8.3.5.3. Genotype of AATD Diagnosed patients in the United Kingdom
8.3.5.4. Comorbidity associated with AATD in the United Kingdom
9. Treatment
9.1. Current therapies
9.1.1. Augmentation Therapy
9.1.2. Gene Therapy strategies
9.1.3. Lifestyle Changes
9.1.4. Novel therapeutics
10. Treatment Algorithm
10.1. Management of Alpha-Antitrypsin (AAT) Deficiency with Lung Disease
10.2. Management of Alpha-Antitrypsin (AAT) Deficiency with Liver Disease
11. Unmet Needs
12. Organizations contributing toward Alpha Antitrypsin Deficiency
13. Case Reports
13.1. An unusual case of alpha-1-antitrypsin deficiency: SZ/Z
13.2. The Importance of Early Identification of Alpha-1 Antitrypsin Deficiency
13.3. A New SERPINA-1 Missense Mutation Associated with Alpha-1 Antitrypsin Deficiency and Bronchiectasis
14. Marketed Drugs
14.1. Prolastin C: Grifols
14.1.1. Drug Description
14.1.2. Mechanism of Action
14.1.3. Regulatory Milestones
14.1.4. Advantages and Disadvantages
14.1.5. Safety and Efficacy of Prolastin-C
14.2. Glassia: Kamada
14.2.1. Drug Description
14.2.2. Mechanism of Action
14.2.3. Regulatory Milestones
14.2.4. Advantages and Disadvantages
14.2.5. Safety and Efficacy of Glassia
14.3. Aralast: Shire
14.3.1. Drug Description
14.3.2. Mechanism of Action
14.3.3. Regulatory Milestones
14.3.4. Advantages and Disadvantages
14.3.5. Safety and Efficacy of Aralast
14.4. Zemaira: CSL Behring
14.4.1. Drug Description
14.4.2. Mechanism of Action
14.4.3. Regulatory Milestones
14.4.4. Advantages and Disadvantages
14.4.5. Safety and Efficacy of Zemaira
14.5. Alfalastin: LFB Biotechnologies
14.5.1. Description
14.5.2. Regulatory Milestones
14.5.3. Advantages and Disadvantages
14.5.4. Safety and Efficacy
14.6. Trypsone: Grifols
14.6.1. Description
14.6.2. Regulatory Milestones
14.6.3. Advantages and Disadvantages
14.6.4. Efficacy and Safety
15. Emerging Therapies
15.1. Inhaled AAT (Glassia IH): Kamada Ltd
15.1.1. Product Description
15.1.2. Regulatory Milestones
15.1.3. Product Development Activities
15.1.4. Clinical Development
15.1.4.1. Clinical Trials Information
15.1.5. Safety and Efficacy
15.2. ALN-AAT02: Alnylam Pharmaceuticals
15.2.1. Product Description
15.2.2. Product Development Activities
15.2.3. Clinical development
15.2.3.1. Clinical Trials Information
15.2.4. Safety and Efficacy
15.3. ARO-AAT: Arrow Head Pharmaceuticals
15.3.1. Product Description
15.3.2. Product Development Activities
15.3.3. Clinical Development
15.3.3.1. Clinical Trials Information
15.3.4. Safety and Efficacy
15.4. VX-814: Vertex Pharmaceuticals
15.4.1. Product Description
15.4.2. Product Development Activities
15.4.3. Clinical Development
15.4.3.1. Clinical Trials Information
15.5. Alvelestat (MPH-966): Mereo Biopharma
15.5.1. Product Description
15.5.2. Product Development Activities
15.5.3. Clinical Development
15.5.3.1. Clinical Trials Information
15.6. DCR-A1AT: Dicerna Pharmaceuticals
15.6.1. Product Description
15.6.2. Product Development Activities
15.6.3. Clinical Development
15.6.3.1. Clinical Trial Information
15.6.4. Pre-clinical Results
16. Other Promising Candidates
16.1. INBRX-101: Inhibrx
16.1.1. Product Description
16.1.2. Product Development Activities
16.1.3. Clinical development
16.2. Carbamazepine: Novartis Pharmaceuticals
16.2.1. Product Description
16.2.2. Clinical Development
16.2.2.1. Clinical Trials Information
16.3. VX-864: Vertex Pharmaceuticals
16.3.1. Product Description
17. Alpha Antitrypsin Deficiency: 6 Major Market Analysis
17.1. Total Market Size of AATD
18. Alpha Antitrypsin Deficiency: Country-Wise Market Analysis
18.1. United States
18.1.1. Total Market Size of AATD
18.1.2. Market Size of Alpha Antitrypsin Deficiency by Therapies in United States
18.2. EU-5
18.2.1. Germany
18.2.1.1. Total Market Size of AATD in Germany
18.2.1.2. Market Size of Alpha Antitrypsin Deficiency by Therapies in Germany
18.2.2. France
18.2.2.1. Total Market Size of AATD in France
18.2.2.2. Market Size of Alpha Antitrypsin Deficiency by Products in France
18.2.3. Italy
18.2.3.1. Total Market Size of AATD in Italy
18.2.3.2. Market Size of Alpha Antitrypsin Deficiency by Products in Italy
18.2.4. Spain
18.2.4.1. Total Market Size of AATD in Spain
18.2.4.2. Market Size of Alpha Antitrypsin Deficiency by Products in Spain
18.2.5. United Kingdom
18.2.5.1. Total Market Size of AATD in The UK
18.2.5.2. Market Size of Alpha Antitrypsin Deficiency by Products in UK
19. Grifols Initiatives towards Alpha Antitrypsin deficiency
20. US FDA Initiatives for patients with Alpha-1 Antitrypsin Deficiency (AATD)
21. Market Drivers
22. Market Barriers
23. Access and Reimbursement Overview of Alpha Antitrypsin Deficiency
23.1. The Italian Experience
23.2. Augmentation Therapy - slowly finding its way in the UK
23.3. The Changing Future
24. Appendix
24.1. Bibliography
24.2. Report Methodology
25. DelveInsight Capabilities
26. Disclaimer
27. About DelveInsight
List of Tables:
Table 1: Summary of Alpha-1 Antitrypsin Deficiency (AATD) Market, Epidemiology, and Key Events (2017–2030)
Table 2: Diagnostic Delay Interval for AATD
Table 3: Total Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6 MM (2017–2030)
Table 4: Prevalence of Symptomatic AATD in the United States (2017–2030)
Table 5: Diagnosed population of AATD in the United States (2017–2030)
Table 6: Genotype of AATD Diagnosed patients in the United States (2017–2030)
Table 7: Comorbidity associated with AATD in the United States (2017–2030)
Table 8: Prevalence of Symptomatic AATD in Germany (2017–2030)
Table 9: Diagnosed population of AATD in Germany (2017–2030)
Table 10: Genotype of AATD Diagnosed patients in Germany (2017–2030)
Table 11: Comorbidity associated with AATD in Germany (2017–2030)
Table 12: Prevalence of Symptomatic AATD in France (2017–2030)
Table 13: Diagnosed population of AATD in France (2017–2030)
Table 14: Genotype of AATD Diagnosed patients in France (2017–2030)
Table 15: Comorbidity associated with AATD in France (2017–2030)
Table 16: Prevalence of Symptomatic AATD in Italy (2017–2030)
Table 17: Diagnosed population of AATD in Italy (2017–2030)
Table 18: Genotype of AATD Diagnosed patients in Italy (2017–2030)
Table 19: Comorbidity associated with AATD in Italy (2017–2030)
Table 20: Prevalence of Symptomatic AATD in Spain (2017–2030)
Table 21: Diagnosed population of AATD in Spain (2017–2030)
Table 22: Genotype of AATD Diagnosed patients in Spain (2017–2030)
Table 23: Comorbidity associated with AATD in Spain (2017–2030)
Table 24: Prevalence of Symptomatic AATD in The United Kingdom (2017–2030)
Table 25: Diagnosed population of AATD in The United Kingdom (2017–2030)
Table 26: Genotype of AATD Diagnosed patients in The United Kingdom (2017–2030)
Table 27: Comorbidity associated with AATD in The United Kingdom (2017–2030)
Table 28: Organizations contributing toward Alpha-Antitrypsin Deficiency
Table 29: Inhaled AAT, Clinical Trial Description, 2020
Table 30: ALN-AAT02, Clinical Trial Description, 2020
Table 31: ARO-AAT, Clinical Trial Description, 2020
Table 32: VX-814, Clinical Trial Description, 2020
Table 33: Alvelestat, Clinical Trial Description, 2020
Table 34: DCR-A1AT, Clinical Trial Description, 2020
Table 35: INBRX-101, Clinical Trial Description, 2020
Table 36: Carbamazepine, Clinical Trial Description, 2020
Table 37: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017–2030)
Table 38: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017–2030)
Table 39: US Market Size of Alpha Antitrypsin Deficiency by Products in USD, Million (2017 -2030)
Table 40: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017-2030)
Table 41: Germany Market Size of Alpha Antitrypsin Deficiency by Products in USD, Million (2017 -2030)
Table 42: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017-2030)
Table 43: France Market Size of Alpha Antitrypsin Deficiency by Products in USD, Million (2017-2030)
Table 44: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017 -2030)
Table 45: Italy Market Size of Alpha Antitrypsin Deficiency by Products in USD, Million (2017-2030)
Table 46: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017 -2030)
Table 47: Spain Market Size of Alpha Antitrypsin Deficiency by Products in USD, Million (2017-2030)
Table 48: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017-2030)
Table 49: UK Market Size of Alpha Antitrypsin Deficiency by Products in USD, Million (2017 -2030)
List of Figures
Figure 1: Swot Analysis
Figure 2: Historical Overview Of AATD Development
Figure 3: Symptoms Associated With Alpha Antitrypsin Deficiency
Figure 4: Risk Factors For AATD
Figure 5: Inheritance Of AATD
Figure 6: Inheritance Pattern Of AATD
Figure 7: Alpha-1 Antitrypsin Binds And Inactivates Neutrophil Elastase.
Figure 8: Pathogenesis Of Alpha Antitrypsin Deficiency
Figure 9: Diagnostic Algorithm Of Alpha Antitrypsin Deficiency
Figure 10: Ats/Ers Diagnostic Recommendations For Alpha Antitrypsin Deficiency
Figure 11: Ats/Ers Recommendations (To Be Discussed) For Alpha Antitrypsin Deficiency
Figure 12: Ats/Ers Diagnostic Recommendations (Not Recommended) For Alpha Antitrypsin Deficiency
Figure 13: Diagnostic And Monitoring Methods For Alpha Antitrypsin Deficiency
Figure 14: Total Prevalent Population Of Alpha-1-Antitrypsin Deficiency In 6 Mm (2017–2030)
Figure 15: Prevalence Of Symptomatic AATD In The United States (2017–2030)
Figure 16: Diagnosed Population Of AATD In The United States (2017–2030)
Figure 17: Genotype Of AATD Diagnosed Patients In The United States (2017–2030)
Figure 18: Comorbidity Associated With AATD In The United States (2017–2030)
Figure 19: Prevalence Of Symptomatic AATD In Germany (2017–2030)
Figure 20: Diagnosed Population Of AATD In Germany (2017–2030)
Figure 21: Genotype Of AATD Diagnosed Patients In Germany (2017–2030)
Figure 22: Comorbidity Associated With AATD In Germany (2017–2030)
Figure 23: Prevalence Of Symptomatic AATD In France (2017–2030)
Figure 24: Diagnosed Population Of AATD In France (2017–2030)
Figure 25: Genotype Of AATD Diagnosed Patients In France (2017–2030)
Figure 26: Comorbidity Associated With AATD In France (2017–2030)
Figure 27: Prevalence Of Symptomatic AATD In Italy (2017–2030)
Figure 28: Diagnosed Population Of AATD In Italy (2017–2030)
Figure 29: Genotype Of AATD Diagnosed Patients In Italy (2017–2030)
Figure 30: Comorbidity Associated With AATD In Italy (2017–2030)
Figure 31: Prevalence Of Symptomatic AATD In Spain (2017–2030)
Figure 32: Diagnosed Population Of AATD In Spain (2017–2030)
Figure 33: Genotype Of AATD Diagnosed Patients In Spain (2017–2030)
Figure 34: Comorbidity Associated With AATD In Spain (2017–2030)
Figure 35: Prevalence Of Symptomatic AATD In The United Kingdom (2017–2030)
Figure 36: Diagnosed Population Of AATD In The United Kingdom (2017–2030)
Figure 37: Genotype Of AATD Diagnosed Patients In The United Kingdom (2017–2030)
Figure 38: Comorbidity Associated With AATD In The United Kingdom (2017–2030)
Figure 39: Treatment Recommendations For AATD
Figure 40: Available Therapeutics Of Alpha Antitrypsin Deficiency
Figure 41: Strategies For Delivery Of Engineered Nucleases: A) Ex-Vivo ; B) In Vivo
Figure 42:Genome Editing With Engineered Nucleases
Figure 43: Treatment Algorithm Of Alpha Antitrypsin Deficiency
Figure 44: Algorithm For Management Of Alpha Antitrypsin Deficiency With Lung Disease
Figure 45: Algorithm For Management Of Alpha Antitrypsin Deficiency With Lung Disease
Figure 46: Current Unmet Needs
Figure 47: Total Market Size Of Alpha Antitrypsin Deficiency In USD, Million (2017–2030)
Figure 48: Total Market Size Of Alpha Antitrypsin Deficiency In USD, Million (2017–2030)
Figure 49: Us Market Size Of Alpha Antitrypsin Deficiency By Products In USD, Million (2017 -2030)
Figure 50: Total Market Size Of Alpha Antitrypsin Deficiency In USD, Million (2017-2030)
Figure 51: Germany Market Size Of Alpha Antitrypsin Deficiency By Products In USD, Million (2017-2030)
Figure 52: Total Market Size Of Alpha Antitrypsin Deficiency In USD, Million (2017-2030)
Figure 53: France Market Size Of Alpha Antitrypsin Deficiency By Products In USD, Million (2017-2030)
Figure 54: Total Market Size Of Alpha Antitrypsin Deficiency In USD, Million (2017 -2030)
Figure 55: Italy Market Size Of Alpha Antitrypsin Deficiency By Products In USD, Million (2017-2030)
Figure 56: Total Market Size Of Alpha Antitrypsin Deficiency In USD, Million (2017 -2030)
